TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Anthelminthics and Multivitamins for Treatment of Severe Anemia in Pregnant Women and Children 6-24 Months of Age in Pakistan
Brief Summary: The purpose of this study is to test the efficacy of two enhanced regimens (deworming and multivitamins) in the treatment of severe anemia in pregnant women and children 6-24 months of age in Karachi, Pakistan.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Anti-Giardia and antihelmintic treatment (secnidazole or albendazole), Drug: Anti-Giardia treatment only (secnidazole or albendazole), Drug: Control group (placebo) | Intervention Type: DRUG; Name: Anti-Giardia and antihelmintic treatment (secnidazole or albendazole); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Anti-Giardia treatment only (secnidazole or albendazole); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Control group (placebo); Assigned to Arm(s): 1
B: Intervention Type: DRUG; Name: Albendazole (400 mg) and/or Vitamin a; Assigned to Arm(s): N/A
C: Arm Label: Alternative SoF; Type: EXPERIMENTAL; Interventions: Other: Alternative summary of findings table format | Arm Label: Current SoF; Type: ACTIVE_COMPARATOR; Interventions: Other: Current summary of findings table format | Intervention Type: OTHER; Name: Alternative summary of findings table format; Assigned to Arm(s): Alternative SoF | Intervention Type: OTHER; Name: Current summary of findings table format; Assigned to Arm(s): Current SoF
D: Arm Label: 1; Type: OTHER; Interventions: Dietary Supplement: Iron-folic acid and mebendazole | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Mebendazole | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multivitamins | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Mebendazole + Multivitamin | Intervention Type: DIETARY_SUPPLEMENT; Name: Iron-folic acid and mebendazole; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Mebendazole; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamins; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Mebendazole + Multivitamin; Assigned to Arm(s): 4

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PPAR Alpha: A Phase 2 Dose-Finding and Safety Study for Atherogenic Dyslipidemia by Eli Lilly
Brief Summary: The purposes of this study are to determine:

* The safety of the study medication and any side effects that might be associated with it;
* Whether the study medication can help patients with low levels of 'good' cholesterol (HDL-C) and high blood fats or triglycerides (TG);
* How much of the study medication should be given to patients;
* How the study medication compares to fenofibrate (Lofibra), a drug used for people with low levels of HDL-C and high levels of TG.


Options:
A: Intervention Type: DRUG; Name: amlodipine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
B: Arm Label: active treatment; Type: EXPERIMENTAL; Interventions: Drug: atorvastatin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): active treatment | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo atorvastatin | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo atorvastatin; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: PPAR alpha; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Use of Heliox Driven Racemic Epinephrine Nebulization in the Treatment of Moderate to Severe Bronchiolitis in Pediatric Emergency Department Patients
Brief Summary: The purpose of this study is to assess whether children with moderate to severe bronchiolitis treated with standard racemic epinephrine therapy via 70:30 helium-oxygen (heliox) driven nebulization will have improvements in measurements of airway more rapidly than those treated with conventional air-oxygen driven nebulization.


Options:
A: Arm Label: Nebulized 3% Saline; Type: EXPERIMENTAL; Interventions: Drug: Nebulized 3% saline | Arm Label: Nebulized 0.9% Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nebulized 0.9% Normal Saline | Intervention Type: DRUG; Name: Nebulized 3% saline; Assigned to Arm(s): Nebulized 3% Saline | Intervention Type: DRUG; Name: Nebulized 0.9% Normal Saline; Assigned to Arm(s): Nebulized 0.9% Normal Saline
B: Intervention Type: DRUG; Name: Epinephrine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: albuterol (salbutamol); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: nebulized epinephrine and nebulized albuterol; Assigned to Arm(s): N/A
D: Arm Label: heliox; Type: OTHER; Interventions: Drug: heliox | Arm Label: oxygen; Type: OTHER; Interventions: Drug: oxygen | Intervention Type: DRUG; Name: heliox; Assigned to Arm(s): heliox | Intervention Type: DRUG; Name: oxygen; Assigned to Arm(s): oxygen

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to investigate the efficacy of Indomethacin compared to Magnesium Sulfate (MgSO4) in reducing neonatal morbidity through a prospective double blind randomized clinical trial. The specific aim of the project is to test the hypothesis that Indomethacin, compared to MgSO4, will decrease the proportion of neonates diagnosed with major complications or death.


Options:
A: Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Magnesium sulfate; Assigned to Arm(s): N/A
B: Arm Label: Magnesium sulphate; Type: EXPERIMENTAL; Interventions: Drug: Magnesium Sulfate | Arm Label: Ritodrine; Type: EXPERIMENTAL; Interventions: Drug: Ritodrine | Arm Label: Calcium channel blocker; Type: EXPERIMENTAL; Interventions: Drug: Calcium Channel Blockers | Intervention Type: DRUG; Name: Magnesium Sulfate; Assigned to Arm(s): Magnesium sulphate | Intervention Type: DRUG; Name: Ritodrine; Assigned to Arm(s): Ritodrine | Intervention Type: DRUG; Name: Calcium Channel Blockers; Assigned to Arm(s): Calcium channel blocker
C: Arm Label: Indomethacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Indomethacin | Arm Label: Nifedipine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nifedipine | Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): Indomethacin | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Nifedipine
D: Arm Label: Nifedipine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nifedipine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nifedipine | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Nifedipine, Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open Label Study Evaluating the Safety and Efficacy of Long-Term Dosing of AMG 531 in Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Brief Summary: The purpose of this study is to determine the safety of romiplostim as a long-term treatment in thrombocytopenic subjects with ITP, to evaluate the long-term platelet response to romiplostim, and to evaluate changes in patient reported outcomes due to the use of romiplostim. Participants must have previously completed a romiplostim ITP study.


Options:
A: Arm Label: Treatment arm plus standard of care; Type: EXPERIMENTAL; Interventions: Drug: eltrombopag | Arm Label: placebo plus standard of care; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: eltrombopag; Assigned to Arm(s): Treatment arm plus standard of care | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo plus standard of care
B: Arm Label: Romiplostim; Type: EXPERIMENTAL; Interventions: Biological: Romiplostim | Intervention Type: BIOLOGICAL; Name: Romiplostim; Assigned to Arm(s): Romiplostim
C: Arm Label: AMG 531; Type: EXPERIMENTAL; Interventions: Biological: AMG 531 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: AMG 531; Assigned to Arm(s): AMG 531 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Romiplostim; Type: EXPERIMENTAL; Interventions: Biological: Romiplostim | Arm Label: Standard of Care; Type: OTHER; Interventions: Drug: Medical Standard of Care for ITP | Intervention Type: DRUG; Name: Medical Standard of Care for ITP; Assigned to Arm(s): Standard of Care | Intervention Type: BIOLOGICAL; Name: Romiplostim; Assigned to Arm(s): Romiplostim

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Omega-3 for Depression and Other Cardiac Risk Factors
Brief Summary: This study will determine the effects of omega-3 fatty acid (FA) augmentation of sertraline on depression and cardiac endpoints after myocardial infarction (MI).


Options:
A: Arm Label: Sertraline/omega-3 supplement; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline/omega-3 | Arm Label: Sertraline/corn oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sertraline/Corn Oil | Intervention Type: DRUG; Name: Sertraline/omega-3; Assigned to Arm(s): Sertraline/omega-3 supplement | Intervention Type: DRUG; Name: Sertraline/Corn Oil; Assigned to Arm(s): Sertraline/corn oil
B: Arm Label: real-time, face-to-face, video-conferenced CBT (vcCBT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Online cognitive behavioral therapy | Arm Label: self-administered internet-based CBT (iCBT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Online cognitive behavioral therapy | Intervention Type: BEHAVIORAL; Name: Online cognitive behavioral therapy; Assigned to Arm(s): real-time, face-to-face, video-conferenced CBT (vcCBT), self-administered internet-based CBT (iCBT)
C: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-led case management | Intervention Type: BEHAVIORAL; Name: Nurse-led case management; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): B
D: Arm Label: Virtual MBCT Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Adapted MBCT | Arm Label: Virtual Health Enhancement Control; Type: EXPERIMENTAL; Interventions: Behavioral: Cardiac Health Enhancement | Intervention Type: BEHAVIORAL; Name: Adapted MBCT; Assigned to Arm(s): Virtual MBCT Intervention | Intervention Type: BEHAVIORAL; Name: Cardiac Health Enhancement; Assigned to Arm(s): Virtual Health Enhancement Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Omega-3 for Depression and Other Cardiac Risk Factors
Brief Summary: This study will determine the effects of omega-3 fatty acid (FA) augmentation of sertraline on depression and cardiac endpoints after myocardial infarction (MI).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega-3 fatty acids | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Omega-3 fatty acids | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3 fatty acids; Assigned to Arm(s): 1, 2
B: Arm Label: 2:1 EPA/DHA; Type: ACTIVE_COMPARATOR; Interventions: Drug: 2:1 EPA/DHA | Arm Label: High EPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: High EPA | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: 2:1 EPA/DHA; Assigned to Arm(s): 2:1 EPA/DHA | Intervention Type: DRUG; Name: High EPA; Assigned to Arm(s): High EPA | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Sertraline/omega-3 supplement; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline/omega-3 | Arm Label: Sertraline/corn oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sertraline/Corn Oil | Intervention Type: DRUG; Name: Sertraline/omega-3; Assigned to Arm(s): Sertraline/omega-3 supplement | Intervention Type: DRUG; Name: Sertraline/Corn Oil; Assigned to Arm(s): Sertraline/corn oil
D: Arm Label: Infliximab; Type: EXPERIMENTAL; Interventions: Drug: Infliximab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): Infliximab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Omega-3 for Depression and Other Cardiac Risk Factors
Brief Summary: This study will determine the effects of omega-3 fatty acid (FA) augmentation of sertraline on depression and cardiac endpoints after myocardial infarction (MI).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavior therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive Stress Management | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive behavior therapy; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Supportive Stress Management; Assigned to Arm(s): 2
B: Arm Label: Treatment for depression and anxiety; Type: EXPERIMENTAL; Interventions: Other: eHealth intervention | Arm Label: Usual care; Type: OTHER; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: eHealth intervention; Assigned to Arm(s): Treatment for depression and anxiety | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual care
C: Arm Label: Depressed Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducation; Treatment recommendations, Drug: Pharmacotherapy | Arm Label: Depressed Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Non-Depressed Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychoeducation; Treatment recommendations; Assigned to Arm(s): Depressed Intervention | Intervention Type: DRUG; Name: Pharmacotherapy; Assigned to Arm(s): Depressed Intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Depressed Usual Care
D: Arm Label: Sertraline/omega-3 supplement; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline/omega-3 | Arm Label: Sertraline/corn oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sertraline/Corn Oil | Intervention Type: DRUG; Name: Sertraline/omega-3; Assigned to Arm(s): Sertraline/omega-3 supplement | Intervention Type: DRUG; Name: Sertraline/Corn Oil; Assigned to Arm(s): Sertraline/corn oil

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Periodontal Infection and Prematurity Study
Brief Summary: This research project is a multi-center double-blind, parallel, randomized, controlled clinical trial design comparing the efficacy of dental scaling and root planing to control treatment (superficial cleaning) for the prevention of preterm birth in pregnant women with periodontal disease.


Options:
A: Intervention Type: PROCEDURE; Name: Treatment of periodontal disease; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Scaling and root planing | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Scaling and root planing | Intervention Type: PROCEDURE; Name: Scaling and root planing; Assigned to Arm(s): 1, 2
C: Arm Label: Scaling and root planing; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Periodontal scaling and root planing, Procedure: Scaling and root planing | Arm Label: Placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Periodontal scaling and root planing; Assigned to Arm(s): Scaling and root planing | Intervention Type: PROCEDURE; Name: Scaling and root planing; Assigned to Arm(s): Scaling and root planing
D: Arm Label: Periodontal Treatment; Type: EXPERIMENTAL; Interventions: Other: multi-center, randomized, controled periodontal therapy | Intervention Type: OTHER; Name: multi-center, randomized, controled periodontal therapy; Assigned to Arm(s): Periodontal Treatment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Cross-Over Comparative Study of Inhaled Mannitol, Alone and in Combination With Daily rhDNase, in Children With Cystic Fibrosis
Brief Summary: The purpose of this study is to determine the medium term efficacy and safety profile of inhaled mannitol, on its own and also as an additional therapy to rhDNase (pulmozyme). In particular, we will assess the impact on: lung function; airway inflammation; sputum microbiology; exacerbations; quality of life; adverse events; exercise tolerance; total costs of hospital and community care; and cost-effectiveness.


Options:
A: Arm Label: group A; Type: EXPERIMENTAL; Interventions: Other: Inhalable Hypertonic saline 7% + Hyaluronan 0.1% | Arm Label: group B; Type: EXPERIMENTAL; Interventions: Other: Inhalable Hypertonic saline 7% | Intervention Type: OTHER; Name: Inhalable Hypertonic saline 7% + Hyaluronan 0.1%; Assigned to Arm(s): group A | Intervention Type: OTHER; Name: Inhalable Hypertonic saline 7%; Assigned to Arm(s): group B
B: Arm Label: 7% Hypertonic saline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hypertonic saline | Arm Label: Hypertonic xylitol; Type: EXPERIMENTAL; Interventions: Drug: Xylitol | Intervention Type: DRUG; Name: Xylitol; Assigned to Arm(s): Hypertonic xylitol | Intervention Type: DRUG; Name: Hypertonic saline; Assigned to Arm(s): 7% Hypertonic saline
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: mannitol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dornase alpha | Arm Label: 3; Type: OTHER; Interventions: Drug: mannitol + pulmozyme | Intervention Type: DRUG; Name: mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: mannitol + pulmozyme; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Dornase alpha; Assigned to Arm(s): 2
D: Arm Label: Master Study Run-in; Type: N/A; Interventions: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Cross-Over Comparative Study of Inhaled Mannitol, Alone and in Combination With Daily rhDNase, in Children With Cystic Fibrosis
Brief Summary: The purpose of this study is to determine the medium term efficacy and safety profile of inhaled mannitol, on its own and also as an additional therapy to rhDNase (pulmozyme). In particular, we will assess the impact on: lung function; airway inflammation; sputum microbiology; exacerbations; quality of life; adverse events; exercise tolerance; total costs of hospital and community care; and cost-effectiveness.


Options:
A: Arm Label: Dornase alfa; Type: EXPERIMENTAL; Interventions: Drug: Dornase alfa (Pulmozyme), Drug: isotonic saline | Arm Label: isotonic saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dornase alfa (Pulmozyme), Drug: isotonic saline | Intervention Type: DRUG; Name: Dornase alfa (Pulmozyme); Assigned to Arm(s): Dornase alfa, isotonic saline | Intervention Type: DRUG; Name: isotonic saline; Assigned to Arm(s): Dornase alfa, isotonic saline
B: Intervention Type: DRUG; Name: Inhaled mannitol; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: mannitol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dornase alpha | Arm Label: 3; Type: OTHER; Interventions: Drug: mannitol + pulmozyme | Intervention Type: DRUG; Name: mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: mannitol + pulmozyme; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Dornase alpha; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Mannitol | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Cross-Over Comparative Study of Inhaled Mannitol, Alone and in Combination With Daily rhDNase, in Children With Cystic Fibrosis
Brief Summary: The purpose of this study is to determine the medium term efficacy and safety profile of inhaled mannitol, on its own and also as an additional therapy to rhDNase (pulmozyme). In particular, we will assess the impact on: lung function; airway inflammation; sputum microbiology; exacerbations; quality of life; adverse events; exercise tolerance; total costs of hospital and community care; and cost-effectiveness.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: mannitol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dornase alpha | Arm Label: 3; Type: OTHER; Interventions: Drug: mannitol + pulmozyme | Intervention Type: DRUG; Name: mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: mannitol + pulmozyme; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Dornase alpha; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Inhaled mannitol; Assigned to Arm(s): N/A
C: Arm Label: eRapid Nebulizer; Type: EXPERIMENTAL; Interventions: Drug: dornase alfa [Pulmozyme®] | Arm Label: Jet Nebulizer; Type: ACTIVE_COMPARATOR; Interventions: Drug: dornase alfa [Pulmozyme®] | Intervention Type: DRUG; Name: dornase alfa [Pulmozyme®]; Assigned to Arm(s): eRapid Nebulizer | Intervention Type: DRUG; Name: dornase alfa [Pulmozyme®]; Assigned to Arm(s): Jet Nebulizer
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Mannitol | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Cross-Over Comparative Study of Inhaled Mannitol, Alone and in Combination With Daily rhDNase, in Children With Cystic Fibrosis
Brief Summary: The purpose of this study is to determine the medium term efficacy and safety profile of inhaled mannitol, on its own and also as an additional therapy to rhDNase (pulmozyme). In particular, we will assess the impact on: lung function; airway inflammation; sputum microbiology; exacerbations; quality of life; adverse events; exercise tolerance; total costs of hospital and community care; and cost-effectiveness.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: mannitol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dornase alpha | Arm Label: 3; Type: OTHER; Interventions: Drug: mannitol + pulmozyme | Intervention Type: DRUG; Name: mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: mannitol + pulmozyme; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Dornase alpha; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Mannitol | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Inhaled mannitol; Assigned to Arm(s): N/A
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: inhaled mannitol | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo comparator | Intervention Type: DRUG; Name: inhaled mannitol; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo comparator; Assigned to Arm(s): B

Answer: A